Bone Graft Substitutes - Medicare Advantage (Revised)
Summary
Humana Medicare Advantage revised its Bone Graft Substitutes policy effective 11/02/2026, reaffirming coverage for autograft, allograft/DBM, ceramic-based synthetics, and rhBMP-2 under specific conditions, while continuing to exclude bioactive glass, bone marrow aspirate (BMA), cell-based/mesenchymal stem cell products, and P-15 peptide products. Billing teams must verify current coverage criteria align with the policy's FDA-approved indication requirements and apply applicable MAC-specific LCDs by jurisdiction.
Get alerts when payers change rules like this one
We check Humana and other payers every day and email you when a change matches your specialty and state.